Cargando…
Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance
The treatment of advanced, radioiodine refractory, differentiated thyroid cancers (RR-DTCs) has undergone major advancements in the last decade, causing a paradigm shift in the management and prognosis of these patients. Better understanding of the molecular drivers of tumorigenesis and access to ne...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331470/ https://www.ncbi.nlm.nih.gov/pubmed/37435488 http://dx.doi.org/10.3389/fendo.2023.1176731 |
_version_ | 1785070260071694336 |
---|---|
author | Hamidi, Sarah Hofmann, Marie-Claude Iyer, Priyanka C. Cabanillas, Maria E. Hu, Mimi I. Busaidy, Naifa L. Dadu, Ramona |
author_facet | Hamidi, Sarah Hofmann, Marie-Claude Iyer, Priyanka C. Cabanillas, Maria E. Hu, Mimi I. Busaidy, Naifa L. Dadu, Ramona |
author_sort | Hamidi, Sarah |
collection | PubMed |
description | The treatment of advanced, radioiodine refractory, differentiated thyroid cancers (RR-DTCs) has undergone major advancements in the last decade, causing a paradigm shift in the management and prognosis of these patients. Better understanding of the molecular drivers of tumorigenesis and access to next generation sequencing of tumors have led to the development and Food and Drug Administration (FDA)-approval of numerous targeted therapies for RR-DTCs, including antiangiogenic multikinase inhibitors, and more recently, fusion-specific kinase inhibitors such as RET inhibitors and NTRK inhibitors. BRAF + MEK inhibitors have also been approved for BRAF-mutated solid tumors and are routinely used in RR-DTCs in many centers. However, none of the currently available treatments are curative, and most patients will ultimately show progression. Current research efforts are therefore focused on identifying resistance mechanisms to tyrosine kinase inhibitors and ways to overcome them. Various novel treatment strategies are under investigation, including immunotherapy, redifferentiation therapy, and second-generation kinase inhibitors. In this review, we will discuss currently available drugs for advanced RR-DTCs, potential mechanisms of drug resistance and future therapeutic avenues. |
format | Online Article Text |
id | pubmed-10331470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103314702023-07-11 Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance Hamidi, Sarah Hofmann, Marie-Claude Iyer, Priyanka C. Cabanillas, Maria E. Hu, Mimi I. Busaidy, Naifa L. Dadu, Ramona Front Endocrinol (Lausanne) Endocrinology The treatment of advanced, radioiodine refractory, differentiated thyroid cancers (RR-DTCs) has undergone major advancements in the last decade, causing a paradigm shift in the management and prognosis of these patients. Better understanding of the molecular drivers of tumorigenesis and access to next generation sequencing of tumors have led to the development and Food and Drug Administration (FDA)-approval of numerous targeted therapies for RR-DTCs, including antiangiogenic multikinase inhibitors, and more recently, fusion-specific kinase inhibitors such as RET inhibitors and NTRK inhibitors. BRAF + MEK inhibitors have also been approved for BRAF-mutated solid tumors and are routinely used in RR-DTCs in many centers. However, none of the currently available treatments are curative, and most patients will ultimately show progression. Current research efforts are therefore focused on identifying resistance mechanisms to tyrosine kinase inhibitors and ways to overcome them. Various novel treatment strategies are under investigation, including immunotherapy, redifferentiation therapy, and second-generation kinase inhibitors. In this review, we will discuss currently available drugs for advanced RR-DTCs, potential mechanisms of drug resistance and future therapeutic avenues. Frontiers Media S.A. 2023-06-26 /pmc/articles/PMC10331470/ /pubmed/37435488 http://dx.doi.org/10.3389/fendo.2023.1176731 Text en Copyright © 2023 Hamidi, Hofmann, Iyer, Cabanillas, Hu, Busaidy and Dadu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Hamidi, Sarah Hofmann, Marie-Claude Iyer, Priyanka C. Cabanillas, Maria E. Hu, Mimi I. Busaidy, Naifa L. Dadu, Ramona Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance |
title | Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance |
title_full | Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance |
title_fullStr | Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance |
title_full_unstemmed | Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance |
title_short | Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance |
title_sort | review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331470/ https://www.ncbi.nlm.nih.gov/pubmed/37435488 http://dx.doi.org/10.3389/fendo.2023.1176731 |
work_keys_str_mv | AT hamidisarah reviewarticlenewtreatmentsforadvanceddifferentiatedthyroidcancersandpotentialmechanismsofdrugresistance AT hofmannmarieclaude reviewarticlenewtreatmentsforadvanceddifferentiatedthyroidcancersandpotentialmechanismsofdrugresistance AT iyerpriyankac reviewarticlenewtreatmentsforadvanceddifferentiatedthyroidcancersandpotentialmechanismsofdrugresistance AT cabanillasmariae reviewarticlenewtreatmentsforadvanceddifferentiatedthyroidcancersandpotentialmechanismsofdrugresistance AT humimii reviewarticlenewtreatmentsforadvanceddifferentiatedthyroidcancersandpotentialmechanismsofdrugresistance AT busaidynaifal reviewarticlenewtreatmentsforadvanceddifferentiatedthyroidcancersandpotentialmechanismsofdrugresistance AT daduramona reviewarticlenewtreatmentsforadvanceddifferentiatedthyroidcancersandpotentialmechanismsofdrugresistance |